Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Pan, Xuejiao; Lv, Huakun; Liang, Hui; Wang, Ying; Shen, Linzhi; Chen, Fuxing; Chen, Yaping; Hu, Yu
• Is Part Of: Human vaccines & immunotherapeutics. Volume 18:Issue 1(2022)
• Publication Date: 2022-12-31
• Subjects: AEFI (adverse events following immunization) -- DPT-IPV/Hib(diphtheria-pertussis-tetanus-poliomyelitis-Hib combined vaccine) -- surveillance -- vaccination -- safety; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2021.2021711
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Objectives: The aim of this study is to describe the reporting rate of adverse events following immunization (AEFI) with pentavalent vaccine: diphtheria-pertussis-tetanus-poliomyelitis-Haemophilus influenzae type b (DPT-IPV/Hib), and to determine whether the reporting rate of AEFI following DPT-IPV/Hib was higher than the average level of the other vaccines. Methods: Review and describe the AEFI reported to national adverse event following immunization surveillance system (NAEFISS) in Zhejiang province from 2015 to 2020. Reporting rates of AEFI were calculated by age, city, severity of AEFI, categories of AEFI, and reaction categories. The data mining algorithm used in this study was reporting odds ratio (ROR). A value of ROR‑1.96SE >1 (standard error [SE]) was considered as positive signal. Results: NAEFISS received 5726 AEFI reports following DTP-IPV/Hib, with a reporting rate of 20.01/10000 doses. Of the reported AEFI, 202 were serious vaccine product-related reactions, including two cases of anaphylactic shock, five cases of Guillain Barre Syndrome (GBS) and two cases of acute disseminated encephalomyelitis. The reporting rate of fever/redness/induration was the highest among all the clinical diagnosis (14.97/10000 doses). The positive signals were obtained for allergic rash (ROR-1.96SE: 1.36), febrile convulsion (ROR-1.96SE: 1.32) and GBS (ROR-1.96SE: 1.16). Conclusion: The present findings bolstered that the DTP-IPV/Hib administered as the four-dose schedule was generally well tolerated in Chinese infants as we did not identify any new/unexpected safety concern from the NAEFISS during a six-year timespan.